These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 36096533)

  • 1. Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8
    Li A; Chang Y; Song NJ; Wu X; Chung D; Riesenberg BP; Velegraki M; Giuliani GD; Das K; Okimoto T; Kwon H; Chakravarthy KB; Bolyard C; Wang Y; He K; Gatti-Mays M; Das J; Yang Y; Gewirth DT; Ma Q; Carbone D; Li Z
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36096533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel anti-GARP antibody DS-1055a augments anti-tumor immunity by depleting highly suppressive GARP+ regulatory T cells.
    Satoh K; Kobayashi Y; Fujimaki K; Hayashi S; Ishida S; Sugiyama D; Sato T; Lim K; Miyamoto M; Kozuma S; Kadokura M; Wakita K; Hata M; Hirahara K; Amano M; Watanabe I; Okamoto A; Tuettenberg A; Jonuleit H; Tanemura A; Maruyama S; Agatsuma T; Wada T; Nishikawa H
    Int Immunol; 2021 Jul; 33(8):435-446. PubMed ID: 34235533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel GARP humanized mouse model for efficacy assessment of GARP-targeting therapies.
    Guo J; Niu Z; Lv R; Yuan J; Zhang Z; Guan X; Li D; Zhang H; Zhao A; Feng J; Liu D; Zhou X; Gong J
    Int Immunopharmacol; 2024 Mar; 130():111782. PubMed ID: 38442579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-β.
    Metelli A; Wu BX; Riesenberg B; Guglietta S; Huck JD; Mills C; Li A; Rachidi S; Krieg C; Rubinstein MP; Gewirth DT; Sun S; Lilly MB; Wahlquist AH; Carbone DP; Yang Y; Liu B; Li Z
    Sci Transl Med; 2020 Jan; 12(525):. PubMed ID: 31915300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelets subvert T cell immunity against cancer via GARP-TGFβ axis.
    Rachidi S; Metelli A; Riesenberg B; Wu BX; Nelson MH; Wallace C; Paulos CM; Rubinstein MP; Garrett-Mayer E; Hennig M; Bearden DW; Yang Y; Liu B; Li Z
    Sci Immunol; 2017 May; 2(11):. PubMed ID: 28763790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4
    Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal.
    Isoyama S; Mori S; Sugiyama D; Kojima Y; Tada Y; Shitara K; Hinohara K; Dan S; Nishikawa H
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exercise Training Improves Tumor Control by Increasing CD8
    Gomes-Santos IL; Amoozgar Z; Kumar AS; Ho WW; Roh K; Talele NP; Curtis H; Kawaguchi K; Jain RK; Fukumura D
    Cancer Immunol Res; 2021 Jul; 9(7):765-778. PubMed ID: 33839688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
    Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer.
    de Streel G; Bertrand C; Chalon N; Liénart S; Bricard O; Lecomte S; Devreux J; Gaignage M; De Boeck G; Mariën L; Van De Walle I; van der Woning B; Saunders M; de Haard H; Vermeersch E; Maes W; Deckmyn H; Coulie PG; van Baren N; Lucas S
    Nat Commun; 2020 Sep; 11(1):4545. PubMed ID: 32917858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.
    Wall JA; Meza-Perez S; Scalise CB; Katre A; Londoño AI; Turbitt WJ; Randall T; Norian LA; Arend RC
    Gynecol Oncol; 2021 Jan; 160(1):285-294. PubMed ID: 33168307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
    Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surface Expression of TGFβ Docking Receptor GARP Promotes Oncogenesis and Immune Tolerance in Breast Cancer.
    Metelli A; Wu BX; Fugle CW; Rachidi S; Sun S; Zhang Y; Wu J; Tomlinson S; Howe PH; Yang Y; Garrett-Mayer E; Liu B; Li Z
    Cancer Res; 2016 Dec; 76(24):7106-7117. PubMed ID: 27913437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spatial and functional targeting of intratumoral Tregs reverses CD8+ T cell exhaustion and promotes cancer immunotherapy.
    Zhou L; Velegraki M; Wang Y; Mandula JK; Chang Y; Liu W; Song NJ; Kwon H; Xiao T; Bolyard C; Hong F; Xin G; Ma Q; Rubinstein MP; Wen H; Li Z
    J Clin Invest; 2024 May; 134(14):. PubMed ID: 38787791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β-catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody.
    Katoh Y; Yaguchi T; Kubo A; Iwata T; Morii K; Kato D; Ohta S; Satomi R; Yamamoto Y; Oyamada Y; Ouchi K; Takahashi S; Ishioka C; Matoba R; Suematsu M; Kawakami Y
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1/PD-L1 Immune Checkpoint Blockade.
    Budimir N; Thomas GD; Dolina JS; Salek-Ardakani S
    Cancer Immunol Res; 2022 Feb; 10(2):146-153. PubMed ID: 34937730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insight into GARP striking role in cancer progression: application for cancer therapy.
    Lahimchi MR; Eslami M; Yousefi B
    Med Oncol; 2022 Dec; 40(1):33. PubMed ID: 36460874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape.
    Martin CJ; Datta A; Littlefield C; Kalra A; Chapron C; Wawersik S; Dagbay KB; Brueckner CT; Nikiforov A; Danehy FT; Streich FC; Boston C; Simpson A; Jackson JW; Lin S; Danek N; Faucette RR; Raman P; Capili AD; Buckler A; Carven GJ; Schürpf T
    Sci Transl Med; 2020 Mar; 12(536):. PubMed ID: 32213632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.